Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Aubrey Capital Management Ltd

Aubrey Capital Management Ltd cut its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 13.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,900 shares of the biotechnology company's stock after selling 1,200 shares during the period. Axon Enterprise accounts for about 1.7% of Aubrey Capital Management Ltd's holdings, making the stock its 14th biggest position. Aubrey Capital Management Ltd's holdings in Axon Enterprise were worth $4,155,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of AXON. Vanguard Group Inc. raised its holdings in shares of Axon Enterprise by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock valued at $5,019,886,000 after buying an additional 275,959 shares during the last quarter. Geode Capital Management LLC raised its stake in Axon Enterprise by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock valued at $1,095,542,000 after acquiring an additional 65,097 shares during the last quarter. Capital World Investors lifted its position in Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after acquiring an additional 841,772 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Axon Enterprise by 273.8% in the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after purchasing an additional 812,337 shares during the period. Finally, Norges Bank acquired a new position in shares of Axon Enterprise in the fourth quarter valued at approximately $482,081,000. Hedge funds and other institutional investors own 79.08% of the company's stock.

Axon Enterprise Trading Down 0.0%

Axon Enterprise stock traded down $0.02 during trading on Monday, hitting $780.61. The company's stock had a trading volume of 447,138 shares, compared to its average volume of 716,037. The stock's fifty day moving average is $669.47 and its 200 day moving average is $621.44. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise, Inc. has a 1-year low of $279.02 and a 1-year high of $806.64. The stock has a market capitalization of $60.77 billion, a price-to-earnings ratio of 201.71, a P/E/G ratio of 5.17 and a beta of 1.29.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same period in the previous year, the firm earned $1.15 earnings per share. Axon Enterprise's revenue was up 31.3% compared to the same quarter last year. As a group, equities research analysts predict that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on AXON. The Goldman Sachs Group increased their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Bank of America upped their target price on shares of Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Northcoast Research downgraded Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Finally, Barclays lifted their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $699.55.

Insider Activity at Axon Enterprise

In related news, Director Michael Garnreiter sold 87 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $760.00, for a total transaction of $66,120.00. Following the completion of the sale, the director now directly owns 24,653 shares of the company's stock, valued at approximately $18,736,280. This trade represents a 0.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Matthew R. Mcbrady sold 400 shares of the firm's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $718.40, for a total value of $287,360.00. Following the sale, the director now owns 3,492 shares of the company's stock, valued at $2,508,652.80. This represents a 10.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,662 shares of company stock worth $29,739,909. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.